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Abstract
Background: Various patterns of HIV-1 disease progression are described in clinical practice and in research. There is a need
to assess the specificity of commonly used definitions of long term non-progressor (LTNP) elite controllers (LTNP-EC),
viremic controllers (LTNP-VC), and viremic non controllers (LTNP-NC), as well as of chronic progressors (P) and rapid
progressors (RP).
Methodology and Principal Findings: We re-evaluated the HIV-1 clinical definitions, summarized in Table 1, using the
information provided by a selected number of host genetic markers and viral factors. There is a continuous decrease of
protective factors and an accumulation of risk factors from LTNP-EC to RP. Statistical differences in frequency of protective
HLA-B alleles (p-0.01), HLA-C rs9264942 (p-0.06), and protective CCR5/CCR2 haplotypes (p-0.02) across groups, and the
presence of viruses with an ancestral genotype in the ‘‘viral dating’’ (i.e., nucleotide sequences with low viral divergence
from the most recent common ancestor) support the differences among principal clinical groups of HIV-1 infected
individuals.
Conclusions: A combination of host genetic and viral factors supports current clinical definitions that discriminate among
patterns of HIV-1 progression. The study also emphasizes the need to apply a standardized and accepted set of clinical
definitions for the purpose of disease stratification and research.
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Introduction
A continuous spectrum of disease progression rates character-
izes HIV-1 infection. This observation led to various definitions of
clinical progression that are widely used for the designation of
patient subsets: from elite controllers to rapid progressors. It is
not well established how clinical definitions relate to various
determinants of pathogenesis. In particular, a number of host
genetic, immune and virological factors have been associated with
various patterns of disease progression [1,2].
The contribution of host factors to viral load and to disease
progression has now been established at genome level [3,4].
Genetic variants, validated in several genome-wide association
studies, explain 13% of the observed variability in HIV-1 viremia
[3]. The addition of gender, age and residual population structure
to the genetic model increases the figure up to 22% [4]. Estimates
could be improved with more complex and diverse predictive
models.
Among viral factors studied for their association with HIV-1
disease progression, RNA viral load is the best marker [5]. In
addition, HIV DNA levels in peripheral blood mononuclear cells
(PBMCs) have prognostic value early in infection [6]. Viral
phenotypes related to clinical progression include the CXCR4 or
CCR5 coreceptor usage; with CXCR4 use associated with more
rapid progression to AIDS [7]. Several studies describe a
correlation between disease progression and the extent of HIV-1
genetic variation [8,9,10]. From an evolutionary perspective, the
analysis of multiple isolates from the Spanish HIV-1 epidemic
permitted the inference of the ‘‘viral dating’’ of isolate sequences as
an estimation of viral evolution [11]. A subset of long term non-
progressors (LTNPs) carries ancestral viruses (i.e. the estimated
date of the viral nucleotide sequences is close to the seroconversion
time), because of the control of viral replication. In contrast,
individuals with continuous viral evolution carry viruses with
modern dating (i.e. close to the sampling time), reflecting the
ongoing process of viral divergence [12].
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Using this background knowledge, the study aims at re-
evaluating broadly applied clinical definitions of disease progres-
sion: LTNP elite controllers (LTNP-EC), viremic controllers
(LTNP-VC), viremic non controllers (LTNP-NC), chronic pro-
gressors (P) and rapid progressors (RP) under the information
provided by a selected number of viral and host genetic
characteristics. Importantly, the study is not a de-novo genetic
or viral study, rather the combined application of well established
knowledge that should result in a clear readout in small sets of
individuals. The analysis emphasizes, in particular, the character-
istics of the least investigated group of individuals, the rapid
progressors.
Materials and Methods
Ethics statement
The study was approved by the Comite de Etica del Centro
Sanitario Sandoval, C/Sandoval 7, Madrid 28010 and by the
University of Lausanne, Faculty of Medicine Commission d’
Ethique de la Recherche Clinique rue du Bugnon 21, 1005
Lausanne.
Study subjects
We included 64 treatment naı¨ve individuals, from the Centro
Sanitario Sandoval (IMSALUD, Madrid, Spain), and from the
Swiss HIV Cohort Study (www.shcs.ch) that fulfilled criteria for
the various clinical progression definitions (Table 1). In the
absence of standardized definition of the various clinical
progression profiles, we based strict definitions on published
literature [1,2,13,14], and on their broad clinical use. LTNPs
patients, including elite and viremic controllers, from Spain met
the strictest definition of more than 10 years of infection and
undetectable or low viremia. Participants gave informed genetic
consent for the study (which was oral and general for different type
of studies for participants with a long term follow up in the Centro
Sanitario Sandoval), and the study and the consents was approved
by the Committees of the two Centers. Seroconversion date was
estimated from either a documented negative test, less than two
years before the first documented positive test, or biological
criteria of primary infection: incomplete western blot and/or
positive p24 Ag and/or high viremia (.1 million copies per
milliliter of blood). Seroconversion date was defined as the mid-
point between the two dates. These individuals have not been
included in previous genetic studies, with the exception of 10
chronic progressors [3].
Host genetic characterization
Host genetic variants were chosen on the basis of genome-wide
association studies [3,4], or selected from the literature according
to the quality of their supporting evidence (www.hiv-pharmaco-
genomics.org). These included HLA-B alleles associated with
protection or progressive disease, the HCP5 rs2395029 allele
in linkage disequilibrium with HLA-B*5701, the HLA-C-35
(rs9264942) variant, ZNRD1 rs9261174 and HLA-A10 serogroup
alleles in linkage disequilibrium, CCR5 D32 (rs333), CCR2 V64I
(rs1799864), CCR5 haplotypes, and copy number variation of
CCL3L1. CCR5 haplotypes were constructed according to the
published nomenclature [15]; considering 8 polymorphisms in the
CCR5/CCR2 promoter and coding region (rs2856758, rs2734648,
rs1799987, rs1799988, rs1800023, rs1800024, rs333, rs1799864);
CCR5_P1 haplotype is carried by HHE, HHG*1 and HHF*1
haplotypes. HLA typing was done by sequencing, and SNP (single
nucleotide polymorphism) analysis was done by TaqMan. Additive
unweighted genetic scores were used to compile genetic informa-
tion [16]. In this model the impact of each allele is assumed to be
the same except for the sign (i.e. alleles with a protective effect
were added, and risk alleles were subtracted. A simplified score
was applied: CCR5 D32 [score 0,1], CCR2 V64I [0,1,2], CCR5 P1
homozygous [0,22], HLA-C–35 [0,1,2], and protective HLA-B+
[0,1,2] and detrimental HLA-B- alleles [0,21,22]). This simplified
procedure was also applied to estimate allelic frequencies for
groups (e.g. protective HLA B alleles).
Viral load and DNA quantification, PCR amplification and
nucleotide sequencing
Plasma HIV-1 RNA viral load (VL) was quantified with the
Branched DNA Siemens versant HIV RNA 3.0 assay (bDNA), or
the Roche Amplicor with a detection limit of 75 and 50 copies/ml
respectively. Viral set point was defined as the average of viral load
Table 1. Definitions of the five clinical progression groups.
LTNP-EC N Asymptomatic HIV Infection over 10 year after seroconversion
N PlasmaHIV RNA levels without ART that are below the level of detection for the respective assay (e.g.,,75 copies/mL by bDNAor,50 by ultrasensitive PCR).
N Isolated episodes of viremia up to 1000 copies/mL as long as they are not consecutive and represent the minority of all available determinations.
N Longitudinal HIV RNA that includes a minimum of 3 determinations, in the absence of antiretroviral agents, which span at least a 12-month period.
LTNP-VC N Asymptomatic HIV Infection over 10 year after seroconversion.
N Plasma HIV RNA levels without ART that are equal or below 2000 copies/mL.
N Isolated episodes of viremia above 2000 copies/mL as long as such episodes represent the minority of all available determinations.
N Longitudinal HIV RNA that includes a minimum of 3 determinations, in the absence of ART, which span at least a 12-month period.
LTNP-NC N Asymptomatic HIV Infection over 10 year after seroconversion
N Plasma HIV RNA levels above 2.000 copies/mL without ART, in more than 50% of the samples.
P N Symptomatic infection or initiation of ART within 10 years after seroconversion
N Longitudinal HIV RNA that includes a minimum of 3 determinations, in the absence of ART, with a viral set point above 2000 copies/mL
RP N $2 CD4 T cell measurements below 350/mm3 within 3 years after seroconversion, with no value $350 afterwards in the absence of ART.
N And/or, ART initiated within 3 years after seroconversion, and at least one preceding CD4 , 350/mm3.
N And/or, AIDS or AIDS-related Death within 3 years after seroconversion and at least one preceding CD4,350/mm3.
LTNP-EC: long term non-progressor, elite controllers; LTNP-VC: long term non-progressor, viremic controllers; LTNP-NC: long term non-progressor, viremic non
controllers; P: chronic progressors, RP: rapid progressors, ART: antiretroviral therapy. Clinical groups summarize different definitions from the literature [1,2,13,14].
doi:10.1371/journal.pone.0011079.t001
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results after assessment of each individual data and elimination of
VL outliers after seroconversion and before antiretroviral therapy
[3]. PBMC-associated DNA was obtained from 107 cells by
standard methods. HIV DNA was amplified in the C2-V5 region
of the env gene as described [11,12] and sequenced in both
directions. Quantification of DNA, estimated by limiting dilution
PCRs, was expressed as number of copies per million peripheral
mononuclear cells (PBMC).
Phylogenetic analysis of the env gene
For viral phylogenetic analysis and X4/R5 genotype, a 210 bp
fragment in env gene from the distal position of C2 to the middle of
C3 was obtained for each participant. Bulk nucleotide sequences
were edited using the SeqMan version 3.61 (Inc. Dnastar,
Madison, Wis). An estimation of the ‘‘viral dating’’ of nucleotide
sequences was established, as previously reported by Bello et al
[11,12], according to the genetic distance to the reconstructed
origin of the HIV-1 subtype B Spanish epidemic and assuming a
relaxed molecular clock. The estimated dating time of the
ancestral samples studied differs from the sampling time up to
15 years. A similar dating time was obtained when considering as
most recent common ancestor (MRCA), the ancestral virus of the
subtype B epidemic in the Los Alamos Database (USA).
The CXCR4 or the CCR5 phenotype was inferred from the V3
amino acid bulk sequences by the PSSM algorithm in Jensen et al
[17] in (http://indra.mullins.microbiol.washington.edu/pssm/) site.
Results
The study individuals represent the five clinical definitions
summarized in Table 1: LTNP-EC (n = 9), LTNP-VC (n = 7),
LTNP-NC (n = 14), P (n = 10) and RP (n = 24). The characteristics
of the study participants are presented in Table S1.
From LTNP-EC to RP, clinical definitions were associated with
changes in the frequency (depletion) of protective host factors, in
particular the CCR5 protective haplotypes (CCR5_H+/H+,
proportion decreasing from f= 0.78 in EC to 0.33 in RP), the
HLA-B protective alleles (B*2705, *5701, *5101, *1302, codified as
HLA-B+, decreasing from f= 0.39 to 0.04), and the HLA-C-35
rs9264942 variant (decreasing from f= 0.83 to 0.13). The inverse
situation occurred with host markers related with rapid progres-
sion, in particular CCR5_P1 homozygosity (proportion increasing
from 0 in EC to 0.13 in RP), and HLA-B risk alleles (B*1801, HLA-
B*35Px alleles and B22 serogroup, increasing from f= 0.11 to
0.25), Figure 1A. In regression analysis, several of the markers
displayed significant statistical association in their frequency
distribution across clinical definitions: protective HLA-B+
(r2 = 0.93, p = 0.01) and CCR5_H+/H+ (r2 = 0.79, p = 0.02), and
trend association for HLA-C-35 (r2 = 0.75, p = 0.06) and CCR5
D32 (r2 = 0.72, p = 0.07); Figure 2. Consistent with recent data
[18], copy number of CCL3L1 did not discriminate among clinical
groups (average copies per diploid genome; LTNP-EC, 2.1;
LTNP-VC, 2.6; LTNP-NC, 2.1; P, 1.6; RP, 2.2).
Selected viral factors previously associated with HIV clinical
progression were included in our analysis: viral load, viral DNA
load, viral dating, and X4/R5 genotype (Table S1). As expected,
there was a progressive increase in the viral load from LTNP-EC
to the RP. The increase in viral load was significantly associated (p
value,0.0001) with a simple additive score that included the most
valuable genetic markers (HLA-C -35, CCR5 D32, CCR2 V64I,
CCR5_P1/P1, and HLA-B+ and B- alleles), Figure 1B. The
average additive genetic score was 3.0 for EC, 1.5 for LTNP
viremic controllers, 1.3 for LTNP-NC, 0.9 for P, and 20.3 for RP
(p,0.0001). An increase in proviral DNA values was also
associated with the various clinical definitions. Proviral load was
extremely low in LTNP-EC and LTNP-VC (in general, ,5
copies/106 PBMCs). LTNP-NC were, in general, above 30
copies/106, and RP showed values 100 times higher values than
the LTNP-EC and LTNP-VC (Table S1). Thus, although a
precise discrimination across groups is limited by evidence of
overlap of close disease strata, the emphasis is placed on the dosing
of multiple protective and risk alleles that define progression.
An important difference between groups was the presence or
absence of evolution in the viral quasispecies. Chronic and rapid
progressors, presenting a continuous high viral replication carried,
as expected, modern viruses. In contrast, among LTNP-EC and
LTNP-VC, individuals maintained ancestral virus genotypes,
close to the transmitted virus [11,19,20] although residual viral
replication may occur [21,22,23]. The switch from the ancestral to
the modern genotype occurred within the group of LTNP-VC
(Table S1); differences in allelic frequency of various host factors
distinguished these two groups. The additive genetic score was 2.6
among individuals carrying ancestral viruses, vs 1.5 for LTNP
carrying modern viruses, p = 0.08 (Figure 1B).
The possible contribution of the X4/R5 genotype to explain the
differences observed between groups was also assessed. Receptor
use, deduced from the V3 amino acid sequence, was statistically
consistent with an R5 phenotype in viruses from all the studied
patients (Table S1).
Discussion
There are different classifications of HIV-1 patients because of
the distinct criteria used [13]. Classifications based in clinical data
differentiate LTNPs, P and RP [1]. Consideration and inclusion of
viral load measurements allows the definition of additional sub-
categories: LTNP elite controllers, LTNP viremic controllers and
LTNP viremic non-controllers [2].
This study shows that these broadly used clinical definitions of
HIV-1 disease progression are generally supported by the pattern
of distribution and enrichment of viral and host genetic factors.
Among them, the frequencies of protective HLA-B alleles, HLA-C-
35 rs9264942, and protective CCR5/CCR2 alleles as well as the
ancestral/modern genotype were the factors that best discrimi-
nated among groups. The least distinct groups are the LTNP with
(LTNP-VC) or without (LTNP-NC) effective control of viremia
that cannot be readily separated on the basis of host genetic
markers. Analysis of the characteristics of viral sequences
permitted, however, to distinguish within LTNP-VC a subset of
individuals with viruses with ancestral dating – a characteristic of
the LTNP-EC. The lack of viral evolution, which is the basis of the
ancestral characteristic of the sequences, reflects the strict control
of viral replication. The ancestral genotype in LTNP-VC could
have prognostic value; but the limited number of individuals in this
group, that differ solely on the basis of viral dating, does not allow
for greater precision on whether the split within this category will
be of clinical consequence.
The study emphasizes the characteristics of the group described
as RP: very high viral load, few protective host factors and an
increased presence of host genetic progression factors. Depending
on the definition used, approximately 10% of HIV-infected
individuals progress to AIDS within the first two or three years
of HIV-1 infection. Recently, Dalmau et al described detailed
genetic, virologic and clinical analyses of two who progressed in
less than one year [24]. A combination of immunological, genetic,
and viral factors were found contributing to the extremely
pathogenic infection, including the detection of highly replicative
dual tropic X4/R5 viruses [24]. None of the rapid progressors in
HIV-1 Progression Definitions
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the present study had viruses with sequence features associated
with the presence of the more pathogenic X4 variant [7].
The study assessed also the host genetic determinants that
associate with complete control of viral replication, as defined by
the identification of ancestral viral populations –viruses that did
not or minimally evolve from the founder ancestral sequence.
Individuals carrying ancestral viruses have an enrichment of host
protective viruses compared with those carrying modern viral.
Viral dating methodology is a rapid approach to measure,
within a given individual and in a single sample, viral evolution.
This methodology has limitations [25] but it has shown it
usefulness for the classification of LTNP [11,12]. Although there
is a global control of viral replication which maintains the
characteristic ancestral genotype, several reports have provided
evidence of residual viral replication in elite controllers
[21,22,26]. The contribution of this residual viremia to viral
Figure 1. Distribution of protective and risk alleles and genetic score across clinical definitions of disease progression. Panel A.
Participants fulfilled criteria for the definition of long term non-progressor elite controllers (LTNP-EC), LTNP viremic controllers (LTNP-VC), LTNP
viremic non controllers (LTNP-NC), chronic progressors (P), and rapid progressors (RP). Analysis included genotyping for HLA-C-35 (rs9264942) (HLA-
C), CCR5 D32 (rs333) and CCR2 V64I (rs1799864) and other polymorphisms in the CCR5 promoter region (rs2856758, rs2734648, rs1799987, rs1799988,
rs1800023, rs1800024) that define protective (CCR5_H+) or risk haplotypes (CCR5_HHE or CCR5_P1), ZNRD1 rs9261174, and alleles in the HLA-A and
HLA-B loci, including protective (HLA2A+, HLA2B+) and risk (HLA2A2, HLA2B2) alleles. For CCR5 haplotypes, the proportion of individuals carrying
protective or risk genotypes are reported. The allelic frequency is represented for other genetic markers. For clarity, protective factors are represented
on the positive Y-axis and risk factors on the negative Y-axis. The specific alleles and haplotypes considered are indicated in the text and Table S1.
Panel B. Correlation between viral load and a simple additive genetic score that includes the most valuable genetic markers as explained in Materials
and Methods section: The distribution of the various clinical definition groups in color coded (LTNP-EC, blue; LTNP-VC, dark green; LTNP-NC, light
green; P, orange; RP, red).
doi:10.1371/journal.pone.0011079.g001
HIV-1 Progression Definitions
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evolution in ancestral patients was recently estimated; it showed
that the percentage of evolved sequences represent, in general,
less than 2% of the sequences in the quasispecies [20]. Other
viral factors could also lead to ancestral or modern character-
istics. Virus co-culture was positive in 6 out of 8 patients with a
modern viral genotype (included in the LTNP-VC and -NC);
whereas a viral isolate was recovered from only one of 8 patient
with ancestral viral genotype (LTNP-EC and -VC) [20]. Proviral
loads were significantly higher in LTNPs with modern versus
patients with ancestral viral dating. Viral replication capacity as
well as viral fitness may also contribute to the clinical
presentation. Earlier work has shown that replication capacity
of full primary viral isolates predict viral set-points after stopping
treatment and also correlates with baseline env diversity [9,27].
Recent work has shown the reduced replication capacity of
chimeric viruses with gag-protease from LTNP-EC in com-
parison with chronically infected individuals [28]. Moreover
envelope glycoproteins from virus from LTNP-EC exhibit a
reduced entry capacity [29].
In conclusion, frequently used clinical definitions of patterns of
disease progression are supported by the pattern of enrichment of
validated host genetic markers and virological factors. This is
particularly relevant for the standardization of definitions, in
particular for rapid progression –a spectrum of disease that has
been incompletely investigated, as well as for the discrimination
within viremic controllers LTNPs. Host genetic and viral markers
are also of use to the identification of incongruent assignments, i.e.,
individuals, with host or viral characteristics inconsistent with the
clinical profile, who may signal novel pathogenic factors or
mechanisms. This was indicated by Emu et al. [30] who underscored
the importance of individuals with a LTNP status that lack any of
the recognized protective factors. The study also emphasizes the
need to apply a standardized and accepted set of clinical definitions
for the purpose of disease stratification and research.
Figure 2. Statistical analyses of the distribution of protective and risk alleles across clinical definitions of disease progression.
Patients who fulfilled criteria for the definition of long term non-progressor elite controllers (LTNP-EC), LTNP viremic controllers (LTNP-VC), LTNP non
controllers (LTNP-NC), chronic progressors (P), and rapid progressors (RP). Analysis included genotyping for HLA-C-35 (rs9264942) (HLA-C), CCR5 D32
(rs333) and CCR2 V64I (rs1799864), CCR5 haplotypes (inferred from CCR5 D32, CCR2 V64I and rs2856758, rs2734648, rs1799987, rs1799988, rs1800023,
rs1800024) which define protective (CCR5_H+/H+) or risk haplotypes (CCR5_HHE/HHE or CCR5_P1/P1), ZNRD1 rs9261174, HLA alleles in the HLA-A and
HLA2B loci, including protective (HLA2A+, HLA2B+) and risk (HLA2A2, HLA2B2) alleles, as well as HCP5 rs2395029 allele in linkage disequilibrium
with HLA2B*5701. The allele frequency of each analyzed marker is presented, with the exception of CCR5 haplotypes, where the proportion of
individuals is reported. The specific alleles and haplotypes are shown in Table S1.
doi:10.1371/journal.pone.0011079.g002
HIV-1 Progression Definitions
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Supporting Information
Table S1 Host genetic and viral results. For SNPs, 1 indicates
the most common and 2 the variant allele. CCR5 haplotypes are
presented according to published nomenclature, where CCR5 P1
is included in HHE, HHG*1 and HHF*1 (HHG*2 and HHF*2
were not considered as they include the protective alleles CCR5
Delta 32 and CCR2 V64I). Observed protective HLA alleles
included B*2705, B*5701, B*5101, B*1302, A10 serogroup
(A*2501, A*2601) and A*3201. Risk HLA alleles included
B*35Px (B*3503), B22 serogroup (B*55, B*56), B*1801, A*2402
and A*2301. Participants are classified in the different classes
according to the log of median viral load (Log VL), except for
rapid progressors. For this class, individuals were ordered
decrescendo according to time from seroconversion to CD4
,350. For elite controllers, the occasional blip was not considered
for estimation of median Log VL. * non-B subtype viruses do not
allow viral dating and X4/R5 genotyping. Score: simple additive
genetic score that includes the most valuable genetic markers as
explained in Materials and Methods. Quantification of DNA viral
load, estimated by limiting dilution PCRs, was expressed as
number of copies per million PBMCs. + charge: number of
positive charged amino acids in the V3 loop. Ancest: Ancestral;
Cauc: Caucasian; N.D.: not done; N.A.: not available. Mode
HIV = mode of HIV acquisition; MSM: men having sex with men,
HET: heterosexual, IDU: intravenous drug use. Green: protective
factors; red: risk factors.
Found at: doi:10.1371/journal.pone.0011079.s001 (1.20 MB
PDF)
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